(46 days)
The Denver® PLEURX Pleural Catheter Kit and Denver® PLEURX Home Drainage Kit are indicated for intermittent, longterm drainage of symptomatic, recurrent, malignant pleural effusion. The devices are indicated for the palliation of dyspnea due to malignant pleural effusion and for providing pleurodesis.
The Denver® PLEURX Pleural Catheter Kit (#50-7000) is a sterile device, for single use only, and is not to be resterilized. The kit contains the PLTURX Catheter; a specifically matched drainage line that can be configured for either wall suction or a vacuum bottle; and the components needed to place the catheter within the pleural space and to dress the catheter exit site after placement. The PLEURX Catheter contained in the kit is a flexible, fenestrated silicone catheter with a cuff and a valve. The fenestrated portion of the catheter is inserted into the pleural space utilizing a peel-away introducer (Seldinger technique). The portion of the catheter containing the cuff is tunneled subcutaneously, and the remaining portion is left external to the body. A radiopaque stripe runs the entire length of the catheter. The Denver® PLEURX Home Drainage Kit (#50-7500), an accessory to the Denver® PLEURX Pleural Catheter Kit, is a sterile, disposable device designed for single use only, and is not to be resterilized. The kit contains drainage lines, vacuum bottles, and the components needed to drain the effusion and to redress the catheter exit site.
The provided text describes a 510(k) premarket notification for the "Denver® PLEURX Pleural Catheter Kit" and "Denver® PLEURX Home Drainage Kit." This submission focuses on establishing substantial equivalence to predicate devices, rather than presenting a de novo clinical study with pre-defined acceptance criteria and statistical analysis to "prove" device performance against those criteria.
Therefore, many of the requested elements (like a table of acceptance criteria, sample sizes for test/training sets, expert qualifications, adjudication methods, MRMC studies, standalone performance, and ground truth establishment for training) are not present in this document.
The document details clinical testing that was performed under IDE #930085 to evaluate the device's effectiveness, but it does not specify quantitative acceptance criteria or statistical methodologies to prove meeting them in the way a robust performance study would. Instead, it describes observed outcomes related to the indicated uses.
Here's a breakdown of what can be extracted or inferred from the provided text, and what is not available:
1. Table of Acceptance Criteria and Reported Device Performance
| Acceptance Criteria | Reported Device Performance (as outcomes) |
|---|---|
| Not explicitly stated as quantitative acceptance criteria for this 510(k). | Effectiveness of PLEURX Catheter for Relief of Dyspnea: Subjects showed a significant improvement in their rating of dyspnea after treatment, as determined by the Friedman test. |
| Effectiveness of PLEURX Catheter for Improving the Quality of Life: Subjects experienced a significant improvement in quality of life, as determined by the t-test, including an improved ability to carry out daily activities. | |
| Effectiveness of PLEURX Catheter for Resulting in Pleurodesis: Approximately half of the subjects achieved pleurodesis. No subjects developed a documented symptomatic recurrence of their effusion. |
Explanation: This document is a 510(k) summary, which typically focuses on demonstrating substantial equivalence. While clinical testing was performed and outcomes reported, the text does not present pre-defined numerical "acceptance criteria" against which these outcomes were measured to "prove" device performance in a statistical sense for market clearance. The reported performance refers to the observed results of the clinical evaluation.
2. Sample size used for the test set and the data provenance
- Sample Size: Not specified in this document. The text refers to "subjects" but does not give a number.
- Data Provenance: The clinical evaluation was conducted under IDE #930085. The country of origin is not specified, but the submitter is Denver Biomaterials, Inc. in Golden, Colorado, USA, suggesting the study likely took place in the US. It was a prospective clinical evaluation, as implied by the IDE number and the description of "subjects" receiving treatment.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
- This information is not provided in the document. The clinical evaluation describes patient-reported outcomes (dyspnea rating, quality of life) and a clinical outcome (pleurodesis), which would typically be assessed by treating physicians or study investigators, but specific details on "experts" for ground truth establishment are absent.
4. Adjudication method for the test set
- This information is not provided in the document.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- This information is not applicable/not provided. The device is a pleural catheter kit, not an imaging analysis AI or diagnostic tool where MRMC studies involving human readers and AI assistance would typically be performed.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
- This information is not applicable/not provided. The device is a physical medical device (catheter kit), not a software algorithm.
7. The type of ground truth used
- The "ground truth" in this context refers to the outcomes measured in the clinical evaluation. These include:
- Patient-reported outcomes: Relief of dyspnea (subjective rating), improvement in quality of life (subjective rating).
- Clinical outcomes: Achievement of pleurodesis (a medical condition that would be diagnosed by a physician based on clinical findings and imaging), and absence of symptomatic recurrence of effusion.
8. The sample size for the training set
- This information is not applicable/not provided. This is a physical medical device, not a machine learning algorithm that requires a "training set."
9. How the ground truth for the training set was established
- This information is not applicable/not provided for the reasons stated above.
{0}------------------------------------------------
Summary of Safety and Effectiveness Denver® PLEURX Pleural Catheter Kit Denver® PLEURX Home Drainage Kit
JUN 2 7 1997
SUBMITTER INFORMATION
Denver Biomaterials, Inc. 14998 W. 6th Avenue, Bldg. E700 Golden, Colorado 80401 USA
Lynne Leonard Director, Regulatory Affairs/Quality Assurance
DEVICE COMMON NAME
Patient Care Suction Apparatus
DEVICE CLASSIFICATION NAME
21 CFR 870.5050
IDENTIFICATION OF SUBSTANTIALLY EQUIVALENT DEVICES
The devices are substantially equivalent to the Argyle® Silicone Thoracic Catheter in intended use. They differ in that the Argyle® Silicone Thoracic Catheter is intended for continuous drainage, while the PLEURX Catheter is intended for intermittent, ambulatory drainage.
The devices are substantially equivalent to the Denver® Pleural Effusion Shunt with Externalized Pump Chamber in materials and dimensional specifications. They differ in that the Denver® Pleural Effusion Shunt with Externalized Pump Chamber transfers pleural fluid to the peritoneal cavity, while the PLEURX Catheter transfers fluid to a vacuum source.
Differences between the devices and their predicate devices should not affect their safety or effectiveness.
DEVICE DESCRIPTION:
The Denver® PLEURX Pleural Catheter Kit (#50-7000) is a sterile device, for single use only, and is not to be resterilized. The kit contains the PLTURX Catheter; a specifically matched drainage line that can be configured for either wall suction or a vacuum bottle; and the components needed to place the catheter within the pleural space and to dress the catheter exit site after placement .
{1}------------------------------------------------
The PLEURX Catheter contained in the kit is a flexible, fenestrated silicone catheter with a cuff and a valve. The fenestrated portion of the catheter is inserted into the pleural space utilizing a peel-away introducer (Seldinger technique). The portion of the catheter containing the cuff is tunneled subcutaneously, and the remaining portion is left external to the A radiopaque stripe runs the entire length of the body . . catheter.
The Denver® PLEURX Home Drainage Kit (#50-7500), an accessory to the Denver® PLEURX Pleural Catheter Kit, is a sterile, disposable device designed for single use only, and is not to be The kit contains drainage lines, vacuum bottles, resterilized. and the components needed to drain the effusion and to redress the catheter exit site.
INDICATED USE
The devices are indicated for intermittent, long-term drainage of symptomatic, recurrent, malignant pleural effusion. They are indicated for the palliation of dyspnea due to malignant pleural effusion, and for providing pleurodesis.
BIOCOMPATABILITY TESTING:
The biological safety of the Denver® PLEURX Pleural Catheter Kit has been assured through the selection of materials which are currently used in legally marketed devices.
CLINICAL TESTING:
The Denver® PLEURX Pleural Catheter Kit and Denver® PLEURX Home Drainage Kit were evaluated clinically under IDE #930085.
- Effectiveness of PLEURX Catheter for Relief of Dyspnea 1.
When compared to baseline, subjects showed a significant improvement in their rating of dyspnea after treatment with the PLEURX Catheter, as determined by the Friedman test.
Effectiveness of PLEURX Catheter for Improving the 2. Quality of Life
Subjects experienced a significant improvement in quality of life after treatment with the PLEURX Catheter, as determined by the Although the subjects had serious malignant disease, t-test. they experienced an improved ability to carry out daily activities when their pleural effusions were controlled.
Effectiveness of PLEURX Catheter for Resulting in 3. Pleurodesis
Approximately half of the subjects treated with the PLEURX Catheter achieved pleurodesis while in the study. No subjects in the PLEURX Catheter arm developed a documented symptomatic recurrence of their effusion.
{2}------------------------------------------------
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Ms. Lynne Leonard Director, Regulatory Affairs and Quality Assurance Denver Biomaterials, Inc. 14998 W. 6th Avenue, Bldg. E 700 Golden, Colorado 80401
JUN 27 1397
K971753 Re: Denver® PLEURX Pleural Catheter Kit and Denver® PLEURX Home Drainage Kit Regulatory Class: II (two) Product Code: 74 DWM Dated: May 8, 1997 Received: May 12, 1997
Dear Ms. Leonard:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act). You may, therefore, market the device, subject to the general controls provisions of Act. However, you are responsible to determine that the medical devices you use as components in the kit have either been determined as substantially equivalent under the premarket notification process (Section 510 (k) of the act), or were on the market prior to May 28, 1976, the enactment date of the Medical Device Please note: If you purchase your device components in Amendments. bulk (i.e., unfinished) and further process (e.g., sterilize) you must submit a new 510 (k) before including these components in your kit. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval) it may be subject to additional controls. Existing major regulations affecting your device
{3}------------------------------------------------
Page 2 - Ms. Lynne Leonard
can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, FDA will verify such assumptions. Failure to comply with the CMP regulation may result in requlatory action. In addition, the Food and Drug Administration (FDA) may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
FDA notes that your device will contain sutures for which you have provided evidence that the suture characteristics are not altered by the sterilization process used for the device. However, you should be aware of the following additional information regarding the inclusion of a suture as a component of your device:
- The labeling, packaging and method of sterilization of 1. the suture cannot be changed without prior notification, review and clearance by FDA.
-
- The supplier of the sutures used in your device can not be changed without prior notification, review and clearance by FDA.
In addition, we have determined that your device kit contains lidocaine which is subject to regulation as a drug.
Our substantially equivalent determination does not apply to the drug component of your device. We recommend you first contact the Center for Drug Evaluation and Research before marketing your device with the drug component. For information on applicable Agency requirements for marketing this drug, we suggest you contact:
Director, Division of Drug Labeling Compliance (HFD-310) Center for Drug Evaluation and Research Food and Drug Administration 5600 Fishers Lane Rockville, Maryland 20857 (301) 594-0063
{4}------------------------------------------------
Page 3 - Ms. Lynne Leonard
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Fart 801 and additionally 809 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act, may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Atora J. Callaba
Thomas J. Callahan, Ph.D. Director Division of Cardiovascular, Respiratory, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{5}------------------------------------------------
INDICATIONS FOR USE
| 510 (K) Number: | K 971753 |
|---|---|
| Device Names: | Denver® PLEURX Pleural Catheter Kit,Denver® PLEURX Home Drainage Kit |
| Indications for Use: | The Denver® PLEURX Pleural Catheter Kitand Denver® PLEURX Home Drainage |
and Denver® PLEURX Home Drainage Kit are indicated for intermittent,longterm drainage of symptomatic, recurrent, malignant pleural effusion. The devices are indicated for the palliation of dyspnea due to malignant pleural effusion and for providing pleurodesis.
Concurrence of CDRH, Office of Device Evaluation (ODE)
ui. Daguinal m.D.
6/26/27
Prescription Use: Yes OR
(Per 21 CFR 801.109)
Over-the-Counter Use: No
§ 870.5050 Patient care suction apparatus.
(a)
Identification. A patient care suction apparatus is a device used with an intrathoracic catheter to withdraw fluid from the chest during the recovery period following surgery.(b)
Classification. Class II (performance standards).